CAS 156227-98-4
:Afelimomab
Description:
Afelimomab is a monoclonal antibody that primarily targets the human immune system, specifically the CD4+ T cell subset. It is classified as an immunomodulatory agent and is utilized in the treatment of certain autoimmune diseases and conditions characterized by excessive immune responses. The substance works by modulating the activity of T cells, thereby influencing the immune response and promoting a more balanced immune system. Its mechanism of action involves binding to specific receptors on T cells, which can lead to alterations in cytokine production and T cell activation. Afelimomab has been studied for its potential therapeutic effects in various clinical settings, including inflammatory diseases. As a biologic, it is produced through recombinant DNA technology, and its stability, efficacy, and safety profile are critical factors in its development and application. The CAS number 156227-98-4 uniquely identifies this compound in chemical databases, facilitating research and regulatory processes.
Formula:Unspecified
Synonyms:- Immunoglobulin G3, anti-(human tumor necrosis factor α) F(ab′)2 fragment (mouse monoclonal LU54107 γ3-chain), disulfide with mouse monoclonal LU54107 κ-chain, dimer
- Immunoglobulin G 3 (mouse monoclonal LU54107 F(ab′)2 fragment γ-chain anti-human tumor necrosis factor α), disulfide with mouse monoclonal LU54107 κ-chain, dimer
- Afelimomab
- Segard
Sort by
The purity filter is not visible because current products do not have associated purity data for filtering.
Found 2 products.
Afelimomab
CAS:<p>Anti-TNF alpha monoclonal antibody; used in the treatment of rheumatoid arthritis, Chrohn's disease and plaque psoriasis</p>Afelimomab
CAS:<p>Afelimomab (MAK 195F), a F(ab')2 fragment of an anti-tumor necrosis factor monoclonal antibody, is utilized in sepsis research [1].</p>Color and Shape:Liquid
